CG Oncology, Inc. Common stock
CGON Real Time Price USDRecent trades of CGON by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by CGON's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Methods of treating solid or lymphatic tumors by combination therapy Sep. 17, 2024
-
Patent Title: Methods of treating bladder cancer Mar. 07, 2023
-
Patent Title: Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus cg0070 and an immune checkpoint inhibitor Nov. 15, 2022
-
Patent Title: Methods of treating bladder cancer with an oncolytic virus May. 24, 2022
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of CGON in WallStreetBets Daily Discussion
Recent insights relating to CGON
Recent picks made for CGON stock on CNBC
ETFs with the largest estimated holdings in CGON
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view CGON Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.